Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection

This 2016 observational retrospective study compared the efficacy of quadruple concomitant non-bismuth therapy (amoxicillin, clarithromycin, metronidazole, and a proton pump inhibitor) versus classical triple therapy (amoxicillin, clarithromycin, and a proton pump inhibitor) as first-line treatments for Helicobacter pylori infection. Among 510 patients treated between January 2012 and May 2014, the